Academic Journal
Neurotropin® alleviates nerve damage in a mouse chronic nerve compression model.
| Τίτλος: | Neurotropin® alleviates nerve damage in a mouse chronic nerve compression model. |
|---|---|
| Συγγραφείς: | Shimada T; Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan., Iwahashi T; Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan. Electronic address: kurobuchi0918@ort.med.osaka-u.ac.jp., Suzuki K; Department of Orthopaedic Surgery, Kansai Rosai Hospital, Hyogo, 660-8511, Japan., Kasuya T; Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan., Yoshimura Y; Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan., Konishi K; Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan., Kamata A; R&D Headquarters, Nippon Zoki Pharmaceutical Co., Ltd., Osaka, 541-0046, Japan., Konishi M; Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan., Miyamura S; Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan., Shiode R; Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan., Kazui A; Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan., Oka K; Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan., Okada S; Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan., Tanaka H; Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan; Department of Sports Medical Science, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan. |
| Πηγή: | Journal of pharmacological sciences [J Pharmacol Sci] 2025 Feb; Vol. 157 (2), pp. 88-95. Date of Electronic Publication: 2024 Dec 25. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Japanese Pharmacological Society Country of Publication: Japan NLM ID: 101167001 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1347-8648 (Electronic) Linking ISSN: 13478613 NLM ISO Abbreviation: J Pharmacol Sci Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Kyoto, Japan : Japanese Pharmacological Society, c2003- |
| Ιατρικοί όροι (MeSH): | Sciatic Nerve*/pathology , Sciatic Nerve*/drug effects , Sciatic Nerve*/injuries , Sciatic Nerve*/physiopathology , Nerve Compression Syndromes*/drug therapy , Nerve Compression Syndromes*/pathology , Polysaccharides*/administration & dosage , Analgesics*/administration & dosage , Analgesics*/therapeutic use , Chondroitin Sulfates*/administration & dosage, Neural Conduction/drug effects ; Animals ; Mice, Inbred C57BL ; Disease Models, Animal ; Chronic Disease ; Male ; Administration, Oral ; Mice ; Injections, Subcutaneous |
| Περίληψη: | Chronic nerve compression disorders, such as carpal tunnel syndrome, are common and can significantly impair daily activities due to motor and sensory dysfunctions. Currently, no systemic pharmacotherapy exists for preventing or treating disease progression. This study aims to investigate whether Neurotropin®, an established analgesic, has therapeutic effects. A chronic nerve compression model was created by wrapping a silicone tube around the sciatic nerve in C57BL/6 mice. Nerves were evaluated electrophysiologically and histologically 2 weeks post-surgery. To confirm the preventive effect on disease onset, we administered Neurotropin® subcutaneously. Additionally, continuous subcutaneous administration of Neurotropin® was started 2 weeks post-surgery, and the therapeutic effects were evaluated at 4 and 8 weeks. Furthermore, the therapeutic effects of daily oral administration of Neurotropin®, starting 2 weeks post-surgery, were evaluated at 8 weeks. Significant decreases in nerve conduction velocity and axonal myelination were observed at 2 weeks post-injury. Neurotropin® administration initiated concurrently with model creation did not prevent disease onset at 2 weeks post-surgery. However, starting administration of Neurotropin® 2 weeks post-injury significantly improved outcomes at 8 weeks post-surgery compared to the control group, with continuous subcutaneous and daily oral administration. Neurotropin® may exhibit therapeutic effects for chronic nerve compression disorders. (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.) |
| Competing Interests: | Declaration of competing interest The funding sponsor, Nippon Zoki Pharmaceutical Co., Ltd., had no role in the design of the study; collection, analyses, or interpretation of data; writing of the manuscript; or decision to publish the results. The authors have declared that no further conflict of interest exists. |
| Contributed Indexing: | Keywords: Compression; Electrophysiology; Histology; Neurotropin; Peripheral nerve injuries |
| Substance Nomenclature: | 57657-35-9 (neurotropin) 0 (Polysaccharides) 0 (Analgesics) 9007-28-7 (Chondroitin Sulfates) |
| Entry Date(s): | Date Created: 20250119 Date Completed: 20250502 Latest Revision: 20250522 |
| Update Code: | 20260130 |
| DOI: | 10.1016/j.jphs.2024.12.006 |
| PMID: | 39828397 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1347-8648 |
|---|---|
| DOI: | 10.1016/j.jphs.2024.12.006 |